priors.science/reviews/bladder-cancer-pharmacotherapy

Bladder Cancer Pharmacotherapy

The current evidence on 19 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

19claims tracked
225primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
8 Established · 5 Likely · 3 Uncertain · 1 Doubtful · 2 Refuted  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Intravesical BCG immunotherapy is superior to intravesical chemotherapy for reducing disease progression and recurrence in high-risk non-muscle-invasive bladder cancer.NmibcEstablished96%4
Enfortumab vedotin combined with pembrolizumab is superior to platinum-based chemotherapy as first-line treatment for advanced urothelial carcinoma.First Line AdvancedEstablished93%11
Pembrolizumab prolongs overall survival compared with chemotherapy as second-line treatment for advanced urothelial carcinoma after platinum failure.Salvage AdvancedEstablished91%13
FGFR2/3 genomic alterations reliably predict clinical benefit from erdafitinib in advanced urothelial carcinoma.Biomarker TargetedEstablished89%20
Enfortumab vedotin monotherapy improves overall survival compared with chemotherapy in advanced urothelial carcinoma after platinum and immune checkpoint inhibitor failure.Salvage AdvancedEstablished89%7
Avelumab maintenance therapy prolongs overall survival in patients with advanced urothelial carcinoma that has not progressed after platinum-based chemotherapy.First Line AdvancedEstablished88%17
Erdafitinib improves overall survival compared with chemotherapy in FGFR2/3-altered advanced urothelial carcinoma after platinum and immune checkpoint inhibitor failure.Salvage AdvancedEstablished88%7
Adjuvant nivolumab after radical cystectomy reduces disease recurrence in patients with muscle-invasive urothelial carcinoma at high risk of relapse.Mibc PerioperativeEstablished86%20
Perioperative durvalumab added to neoadjuvant gemcitabine-cisplatin chemotherapy improves event-free survival in muscle-invasive bladder cancer.Mibc PerioperativeLikely84%21
Neoadjuvant cisplatin-based chemotherapy before radical cystectomy improves overall survival in muscle-invasive bladder cancer.Mibc PerioperativeLikely83%7
Oral erdafitinib reduces recurrence compared with intravesical chemotherapy in patients with BCG-unresponsive, FGFR2/3-altered high-risk non-muscle-invasive bladder cancer.NmibcLikely83%20
Pembrolizumab monotherapy provides durable responses as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma.First Line AdvancedLong-standingLikely70%13
Nadofaragene firadenovec gene therapy achieves durable complete responses as an intravesical treatment for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.NmibcLikely70%18
Pembrolizumab achieves durable complete responses in patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer containing carcinoma in situ.NmibcUncertain64%16
Tumour mutational burden (TMB-high ≥10 mut/Mb) predicts pembrolizumab benefit in advanced urothelial carcinoma.Biomarker TargetedLong-standingUncertain56%22
Dose-dense MVAC is superior to gemcitabine-cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer based on pathological response and survival outcomes.Mibc PerioperativeUncertain50%16
PD-L1 expression (CPS or IC scoring) is a reliable predictive biomarker for immune checkpoint inhibitor benefit in advanced urothelial carcinoma.Biomarker TargetedLong-standingDoubtful35%20
Sacituzumab govitecan post-platinumSalvage AdvancedRefuted29%20
Atezolizumab 1L meaningful benefitFirst Line AdvancedLong-standingRefuted16%17
Track Bladder Cancer Pharmacotherapy.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.